Cargando…
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
OBJECTIVE: The aim of this study was to evaluate the efficacy, cardiotoxicity profile and long-term benefits of neoadjuvant therapy in human epidermal growth factor receptor 2-positive operable breast cancer patients. PATIENTS AND METHODS: A total of 142 patients diagnosed from 2005 to 2016 were inc...
Autores principales: | Antolín, Silvia, Acea, Benigno, Albaina, Luis, Concha, Ángel, Santiago, Paz, García-Caballero, Tomás, Mosquera, Joaquín J, Varela, José Ramón, Soler, Rafaela, Calvo, Lourdes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311333/ https://www.ncbi.nlm.nih.gov/pubmed/30643452 http://dx.doi.org/10.2147/BCTT.S179750 |
Ejemplares similares
-
Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
por: Bouzón, Alberto, et al.
Publicado: (2016) -
Evaluation of MRI Accuracy After Primary Systemic Therapy in Breast Cancer Patients Considering Tumor Biology: Optimizing the Surgical Planning
por: Bouzón, Alberto, et al.
Publicado: (2019) -
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017) -
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015) -
The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)